JosephPHorriganMDFAACAP

PubMed

• Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.
  Kennedy, M., Glass, L., Glaze, D., Kaminsky, S., Percy, A., Neul, J., Jones, N., Tropea, D., Horrigan, J., Nues, P., Bishop, K., Youakim, J.> ;Frontiers in Pharmacology. 2023 Jan 1
• 31 citations
  A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)
  Joseph P. Horrigan, Tiago Gomes, Mike Snape, Nikoletta Nikolenko, Alison McMorn, Stuart Evans, Alex Yaroshinsky, Oscar Della Pasqua, Sean Oosterholt, Hanns Lochmüller> ;Pediatric Neurology. 2020 Nov 1
• 26 citations
  A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.
  Geraldine Dawson, Jessica Sun, J.H. Baker, Kimberly L. H. Carpenter, Scott N. Compton, Megan Deaver, Lauren Franz, Nicole Heilbron, Brianna Herold, Joseph P. Horrigan,...> ;The Journal of Pediatrics. 2020 Jul 1
• A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome.
  Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, Hatti S, Snape M, Yaroshinsky A, Stoms G, FXS-001 Investigators, Glass L, Jones NE> ;Pediatric neurology. 2020-05-23
• 25 citations
  A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.
  Daniel G Glaze, Jeffrey L Neul, Alan Percy, Tim Feyma, Arthur Beisang, Alex Yaroshinsky, George Stoms, David Zuchero, Joseph Horrigan, Larry Glass, Nancy E Jones> ;Pediatric Neurology. 2017 Nov 1
• 8 citations
  Assessment of Caregiver Inventory for Rett Syndrome.
  Jane B. Lane, Amber Salter, Nancy E. Jones, Gary Cutter, Joseph P. Horrigan, Steve A. Skinner, Daniel G. Glaze, Jeffrey L. Neul, Alan K. Percy> ;Journal of Autism and Developmental Disorders. 2017 Apr 1
• 24 citations
  Adjunctive Maintenance Lamotrigine for Pediatric Bipolar i Disorder: A Placebo-Controlled, Randomized Withdrawal Study
  Robert L. Findling, Kiki D. Chang, Adelaide S. Robb, Vicki J. Foster, Joseph P. Horrigan, Alok Krishen, Art Wamil, John E. Kraus, Melissa P. DelBello> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2015 Dec 1
• 34 citations
  A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
  L. Fredrik Jarskog, Martin T. Lowy, Richard Grove, Richard S.E. Keefe, Joseph P. Horrigan, M. Patricia Ball, Alan Breier, Robert W. Buchanan, Cameron S. Carter, John G...> ;Schizophrenia Research. 2015 May 1
• 65 citations
  Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder
  Lawrence Scahill, Michael G. Aman, Luc Lecavalier, Alycia K. Halladay, Somer L. Bishop, James W. Bodfish, Sabrina N. Grondhuis, Nancy E. Jones, Joseph P. Horrigan, Edw...> ;Autism. 2015 Jan 1
• 94 citations
  Measuring Anxiety as a Treatment Endpoint in Youth with Autism Spectrum Disorder
  Luc Lecavalier, Jeffrey J. Wood, Alycia K. Halladay, Nancy E. Jones, Michael G. Aman, Edwin H. Cook, Benjamin L. Handen, Bryan H. King, Deborah A. Pearson, Victoria Ha...> ;Journal of Autism and Developmental Disorders. 2014 May 1
• 77 citations
  A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's d...
  Richard Grove, Conn M Harrington, Andreas Mahler, Isabel Jm Beresford, Paul Maruff, Martin T. Lowy, Andrew P Nicholls, Rebecca L. Boardley, Alienor Berges, Pradeep J. ...> ;Current Alzheimer Research. 2014 Jan 1
• 8 citations
  Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis
  Richard Grove, S. Shackelford, Sieghart Sopper, S. Pirruccello, Joseph P. Horrigan, Eva Havrdova, M. Gold, Ole Graff> ;European Journal of Neurology. 2013 Jul 1
• 51 citations
  Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
  David Miller, Thomas Weber, Richard Grove, C. Wardell, Joseph P. Horrigan, Ole Graff, Gillian Atkinson, Pinky Dua, Tarek A. Yousry, David G. MacManus, Xavier Montalban> ;The Lancet. Neurology. 2012 Feb 1
• 9 citations
  Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy.
  John E. Kraus, Joseph P. Horrigan, Douglas J. Carpenter, Rowena Fong, Pamela S. Barrett, John T. Davies> ;Journal of Affective Disorders. 2010 Jan 1
• 20 citations
  From Trial and Error to Trial Simulation. Part 2: An Appraisal of Current Beliefs in the Design and Analysis of Clinical Trials for Antidepressant Drugs
  Gijs W. E. Santen, Joseph P. Horrigan, Meindert Danhof, O Della Pasqua> ;Clinical Pharmacology and Therapeutics. 2009 Sep 1
• 23 citations
  Gepirone Extended-Release in the Treatment of Adult Outpatients With Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study
  Robert J. Bielski, Lynn Cunningham, Joseph P. Horrigan, Peter D. Londborg, Ward T. Smith, Kenneth J. Weiss> ;The Journal of Clinical Psychiatry. 2008 Mar 18
• 19 citations
  A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology.
  Heidi K. Moore, Carroll W. Hughes, James C. Mundt, A. John Rush, Laurie Macleod, Graham J. Emslie, Shailesh Jain, Dayna S. Geralts, Ira H. Bernstein, Joseph P. Horriga...> ;The Journal of Clinical Psychiatry. 2007 Sep 17
• 95 citations
  Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled stud...
  Anita H. Clayton, Harry A. Croft, Joseph P. Horrigan, Donna S. Wightman, Alok Krishen, Nathalie Richard, Jack G. Modell> ;The Journal of Clinical Psychiatry. 2006 May 15
• 5 citations
  Analysis of Electrocardiographic Data Following Use of Paroxetine in Pediatric Depression and Obsessive-Compulsive Disorder
  Stan Krulewicz, David J. Carpenter, Regan Fong, Joseph P. Horrigan, Alan Lipschitz, Philip Perera, Karen Dineen Wagner> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2006 Apr 1
• 106 citations
  Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study
  Timothy E. Wilens, Barbara R. Haight, Joseph P. Horrigan, James J. Hudziak, Norman E. Rosenthal, Daniel F. Connor, Kenneth D. Hampton, Nathalie Richard, Jack G. Modell> ;Biological Psychiatry. 2005 Apr 1
• 5 citations
  Adderall, the atypicals, and weight gain.
  Joseph P. Horrigan, L. Jarrett Barnhill, R. Robin Kohli> ;Journal of the American Academy of Child and Adolescent Psychiatry. 2001 Jun 1
• 7 citations
  Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.
  Joseph P. Horrigan> ;Expert Opinion on Pharmacotherapy. 2001 Apr 1
• 29 citations
  Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder.
  Joseph P. Horrigan, L J Barnhill> ;The Journal of Clinical Psychiatry. 2000 Nov 30
• 24 citations
  Guanfacine and secondary mania in children.
  Joseph P. Horrigan, L. Jarrett Barnhill> ;Journal of Affective Disorders. 1999 Aug 1
• 2 citations
  Diet and the atypical neuroleptics.
  Joseph P. Horrigan, Linmarie Sikich> ;Journal of the American Academy of Child and Adolescent Psychiatry. 1998 Nov 1
• Join now to see all